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BY-NC-ND license (http://creativecomAbstract Background and aim: Raynaud’s phenomenon (RP) is a microvascular disorder char-
acterized by episodic peripheral vasospasm and ischemia and is commonly found in patients
with autoimmune diseases (AID). The vasomotor homoeostasis and endothelial cells damage
are involved in RP. Endothelial microparticles (EMPs) may act as a biomarker for endothelial
damage. The aim of this study is to investigate the correlation between the levels of micropar-
ticles (MPs) and microvasculopathy in AID with RP.
Methods: Thirty-seven patients with AID and RP (RP group) and 27 patients with AID but
without RP (non-RP group) were enrolled. The microvasculopathy score of RP was graded by
nailfold capillary microscopy. The plasma levels of MPs were measured by flow cytometry uti-
lizing specific labels for endothelial MPs (CD105 and CD144) and annexin V staining for phospha-
tidylserine bearing-MPs (annexin VþMPs).
Results: The levels of circulating EMPs (CD105þ p Z 0.005, CD144þ p Z 0.004), and the an-
nexin Vþ MPs (p < 0.001) were significantly elevated in the RP group compared with the
non-RP group. Moreover, the high microvasculopathy scores were closely related with
annexinVþ MPs levels in the RP group (p Z 0.041).
Conclusions: Levels of circulating EMPs and annexin Vþ MPs are elevated in AID patients
with RP indicate the endothelial damage and endothelial dysfunctions. In addition, levels ofof Emergency Medicine, Chang Gung Memory Hospital at Linkou, 5 Fu-Shin Street, Kweishen District,
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Raynaud’s phenomenon (RP) is a microcirculatory disorder
with episodic vasospasm of small arteries and arterioles of
the digits in response to cold or emotional stimuli. RP is
classified as either primary or secondary based on whether
there is an associated disorder. The pathophysiological
abnormalities leading to RP are probably different between
the primary and secondary forms.1 Secondary RP may have
more severe symptoms and cause digital ischemia, ulcera-
tions, and even gangrene. Autoimmune diseases (AID) are
associated with secondary RP, most notably systemic scle-
rosis (SSc) in > 90% cases. RP also occurred in overlap or
mixed connective tissue diseases (85%), systemic lupus er-
ythematosus (SLE; 10e45%), primary Sjo¨gren’s syndrome
(33%), dermatomyositis or polymyositis (20%), and rheu-
matoid arthritis (12.3%).2,3 Nailfold capillary microscopy
provides a morphologic approach to evaluate the severity
of microvasculopathy in RP.4
In RP associated with AID, the vasospasm is more sus-
tained, long-lasting, and highly recurrent, and is associ-
ated with structural alterations of the vessel walls.
Structural alterations of small and medium-sized arteries
can be seen in secondary RP with the features of endo-
thelial proliferation and ineffective neoangiogenesis,
which lead to vascular remodeling.5 CD105, abundantly
expressed in angiogenic endothelial cells, is associated
with proliferation and induced by hypoxia.6 VE-cadherin
(CD144) is also an endothelial protein, and the transi-
tion of its function from the quiescent to the angiogenic
state increases its content through the activation of its
promoter.7 Microparticles (MPs) are small vesicles that
are released by budding plasma membranes after cell
activation or apoptosis.8 Endothelial MPs (EMPs) are
directly indicative of endothelial cell stress/damage, and
may also reflect endothelial inflammation, increased
coagulation, and vascular tone.9 MP-associated procoa-
gulant activities rely on the exposure of phosphati-
dylserine (PS) and are considered to involve the vascular
homeostasis.10 Annexin V interacts strongly and specif-
ically with PS,11 and its presence on MP is a true reflec-
tion of procoagulant activity.12 It is interesting to
correlate the expression of annexin Vþ MP and EMPs of
CD105 and CD144 with the severity of nailfold capillaro-
scopy in AID with RP.Materials and methods
Eligibility of study participants
Sixty-four patients with AID from our Rheumatology clinic
were recruited in this study. Patients with AID whou Y-JJ, et al., The role of endothe
y, Immunology and Infection (201complained of cold intolerance and met the diagnosis of
RP were enrolled as the RP group and those without the
symptoms and signs of RP were enrolled as the non-RP
group. Patients with rheumatoid arthritis, SSc, or SLE
fulfilled the American College of Rheumatology classifi-
cation criteria,13e15 undifferentiated connective tissue
disease fulfilled criteria according to LeRoy et al,16 Sjo¨g-
ren’s syndrome fulfilled AmericaneEuropean Consensus
Group,17 and dermatomyositis fulfilled Bohan criteria18
were included. The patients taking vasodilator drugs,
such as endothelin-1 receptor antagonists, prostacyclin
analogs, type 5 phosphodiesterase inhibitors, or those
having an active infection or thrombosis proven by clinical
and laboratory evaluations were excluded. The study
protocol was approved by the Institutional Review Board
of Chang Gung Memorial Hospital and the protocol strictly
adhered to the Declaration of Helsinki. Signed and
informed consent was obtained from each participant
before blood samples were taken.
Grading of microvasculopathy by nailfold capillary
microscopy
Nailfold capillary microscopy (SMZ-10 stereoscopic micro-
scope, Olympus, Tokyo, Japan) was performed on bilateral
second to fourth fingers at room temperature. Grading of
vascular enlargement, hemorrhagic spots, and avascu-
larity was performed as in our previous study on RP.19
Vascular enlargement, vasodilatation, grading (V score),
avascularity (A score), and nailfold hemorrhagic spots (H
score) were assessed. The H, A, and V scores were calcu-
lated as the summation of scores from the bilateral second
to fourth nailfold in each category and the micro-
vasculopathy score was obtained by summing these three
scores.
Measurement of circulating MPs
Venous blood was collected by atraumatic antecubital
venipuncture using a 21-gauge needle. A 2.5-mL sample of
blood was then collected into a sodium citrate (0.109M)
Vacutainer tube for platelet poor plasma preparation by one
step centrifugation at 1500 g for 20 minutes at room tem-
perature. The levels of circulatingMPsweremeasuredwithin
2 hours of blood collection.MPswere defined as eventswith a
size  1 mm and positively stained by specific fluorochrome-
labeled monoclonal antibodies. All MP analyses were per-
formed using a Coulter EPICS XL flow cytometer with EXPO32
ADC analytical software (Beckman Coulter, Miami, Fla, USA).
The determination ofMP gatewas adapted from themethods
described by Robert.20 Briefly, the light scattered and fluo-
rescence channel were set as a logarithmic gain and cali-
brated fluorescent beads (Megamix, mixed 0.5-mm, 0.9-mm,lial microparticles in autoimmune disease patients with Raynaud’s
6), http://dx.doi.org/10.1016/j.jmii.2015.12.010
Table 1 Baseline characteristics of autoimmune disease
patients with and without Raynaud’s phenomenon (RP).
RP group Non-RP group p
n 37 27
Age (y) 49.7  2.2 47.2  2.2 0.427
Diabetes 0 1 0.238
Hypertension 10 8 0.819
Smoke 4 0 0.078
RA 4 4 0.632
SSc 5 1 0.184
SLE 13 12 0.451
UCTD 11 6 0.502
Sjo¨gren’s syndrome 4 2 0.645
Dermatomyositis 0 2 0.093
Disease duration (y) 6.29  0.98 6.5  1.07 0.89
ACL-G 6.82  1.89 4.64  1.07 0.389
SLEDAI 3.6 2  0.84 3.5  0.42 0.905
White blood cells
(109 /L)
5.98  0.38 5.78  0.37 0.731
Hemoglobin (g/dL) 12.6  0.2 12.46  0.23 0.68
Platelets (1010 /L) 20.8  1.2 22.4  2.1 0.486
Data are presented as mean  standard error of the mean or n.
ACL-G anticardiolipin G antibody; RA Z rheumatoid arthritis;
SScZ systemic sclerosis; SLEZ systemic lupus erythematousus;
SLEDAI systemic lupus erythematousus disease activity index;
UCTD Z undifferentiated connective tissue disease.
Table 2 The microvasculopathy score graded by the




H (hemorrhage) 4.4  0.8 0.6  0.2 < 0.001
A (avascular) 10.1  0.7 0.9  0.2 < 0.001
V (vasodilation) 1.8  0.4 0.2  0.1 < 0.001
Total microvasculopathy
score
16.3  1.4 1.9  0.4 < 0.001
Data are presented as mean  standard error of the mean.
RP Z Raynaud’s phenomenon.
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used for the initial settings and identified in forward scatter
versus side scatter intensity dot plot presentation. A 25-mL
sample of platelet poor plasmawas incubated for 30minutes
in the dark at room temperature with either specific mono-
clonal antibodies (mAbs; 10 mL/test) or the respective
isotype-matched control. The mAbs used for MP analysis
were as follows: phycoerythrin (PE)-conjugated mAb for
CD105 (BD Biosciences, San Diego, CA, USA); PE-conjugated
mAb for CD144 (eBioscence, San Diego, CA, USA). MPs
bearing phophatidylserine were labeled by fluorescein iso-
thiocyanate (FITC)-conjugated annexin V solution (10 mL/
test) (BD Biosciences). Calibrator beads (Flowcount beads,
10 mm, Beckman Coulter) with a known concentration were
added to each samples and run concurrently with the MP
samples. Before the flow cytometry analysis, the sample was
diluted in phosphate buffered saline to a final volume of
500 mL. Sample analysis was stopped when a fixed number
(2500) of calibrated beads had been counted. The concen-
tration ofMPswas determined by comparisonwith that of the
calibrator beads.
Statistical analysis
Statistical analysis was performed with the SPSS software
for Windows version 16.0 (SPSS Software, Chicago, IL, USA).
Quantitative variables with non-normal distribution were
log-transformed. Differences between the groups were
calculated using Student t test or ManneWhitney U test.
The correlations between variables were presented as
Spearman’s correlation coefficients. A p value < 0.05 was
considered statistically significant.
Results
Higher microvasculopathy score in RP group AID
patients
A total of 64 AID patients were enrolled in the study, with
37 in the RP group and 27 in the non-RP group. The char-
acteristics of the participants are shown in Table 1. All
patients were female. Two patients with SLE in RP group
had vasculitis. Of the patients with SSc, 90% demonstrated
secondary RP. The SLE activity was similar in RP and non-RP
SLE patients. The cardiac risk factors of DM, HTN, and
hyperlipidemia, are similar the two groups. In nailfold
capillary microscopy examination, the RP patients showed
higher rates of hemorrhage, and more avascularity and
vasodilation than the non-RP patients (Table 2). Five of the
27 patients without RP did not have any microvascular
lesion and most cases had minor microvascular abnormal-
ities. In contrast, all of the patients in the RP group had
marked microvascular morphological changes and higher
microvasculopathy scores.
Elevated circulating levels of EMPs and annexin
VD MPs in the AID patients with RP
The AID patients with RP revealed significantly elevated
circulating levels of EMPs and annexin Vþ MPs than thePlease cite this article in press as: Wu Y-JJ, et al., The role of endothe
phenomenon, Journal of Microbiology, Immunology and Infection (201non-RP group. The median of CD105þ EMPs (Figure 1A),
CD144þ EMP (Figure 1B) and Annexin Vþ MP (Figure 1C) in
RP group and non-RP was 1164 versus 402 events/mL
(p Z 0.005), 1250 versus 588 events/mL (p Z 0.004) and
764 versus 132 events/mL (p< 0.001), respectively.
Stratified analysis of patients with SLE showed similar
results between two groups with RP and non-RP
(Figure 2). The correlations of the MPs and micro-
vasculopathy scores in the RP and non-RP groups are
presented in Figure 3. Two EMPs, CD105þ EMPs and
CD144þ EMPs, had a positive correlation in both the RP
(r Z 0.6, p< 0.001) and non-RP groups (r Z 0.8,
p< 0.001). The EMP levels were significantly correlated
with annexin Vþ MPs in the RP group (CD105þ EMP,
r Z 0.45, p Z 0.006, CD144þ EMP, r Z 0.51, p Z 0.001),
but not in the non-RP group. The annexin VþMP levels
was positively associated with the avascular and micro-
vasculopathy scores in the RP group (r Z 0.43, pZ 0.008;
r Z 0.34, p Z 0.041, respectively).lial microparticles in autoimmune disease patients with Raynaud’s
6), http://dx.doi.org/10.1016/j.jmii.2015.12.010
Figure 1. Circulating (A,B) endothelial microparticle (EMP)
and (C) annexin Vþ microparticle (MP) levels in autoimmune
disease patients. RP Z Raynaud’s phenomenon.
Figure 2. Circulating (A,B) endothelial microparticle (EMP)
and (C) annexin Vþ microparticle (MP) levels in systemic lupus
erythematous patients. RP Z Raynaud’s phenomenon.
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Endothelial damage is thought to contribute to the micro-
vascular injury in secondary RP as SSc patients have a
higher level of von Willebrand factor compared with pa-
tients with primary RP and healthy controls.21 Several
vasoactive mediators, such as nitric oxide,22 endothelin-
1,23 and angiotensin II24 have also been reported to be
increased in the blood levels of patients with secondary RP.
These findings suggest the potential role of endothelial
activation in the pathogenesis of secondary RP. The current
study demonstrated increased EMP levels in the AID and SLE
subgroup patients with RP. Circulating EMPs have been
considered to serve as a potential marker of endothelial
activation and damage in various autoimmune disorders,
and higher EMP levels have been detected in patients with
vasculitis and associated with disease activation.25,26Please cite this article in press as: Wu Y-JJ, et al., The role of endothe
phenomenon, Journal of Microbiology, Immunology and Infection (201Higher plasma EMPs have been reported in SLE patients
with a state of low disease activity compared to healthy
donors.27 EMPs were elevated in active SLE and associated
with increased endothelial damage and dysfunction, which
decreased after suppression of clinical activity and
inflammation.28 The present study demonstrated that the
level of EMPs in the SLE patients with RP is higher than
those without RP. This suggests that more endothelial
dysfunction in SLE patients with RP. Furthermore, elevated
levels of circulating EMPs in other AID patients with RP are
also found. EMPs may serve as a potential surrogate
biomarker to reflect the endothelial activation and damage
in secondary RP.
VE-cadherin (CD144) is an integral membrane protein of
interendothelial adherens junctions that maintains vascular
integrity.29 Reduced VE-cadherin expression at the inter-
endothelial junctions has been demonstrated to occur in
response to the ischemiaereperfusion injury and to be
associated with increasing microvascular permeability.30lial microparticles in autoimmune disease patients with Raynaud’s
6), http://dx.doi.org/10.1016/j.jmii.2015.12.010
Figure 3. Correlograms of the microvasculopathy score and
microparticle (MP) levels in autoimmune disease patients (A)
with and (B) without Raynaud’s phenomenon (RP).
A Z avascular area score; H Z hemorrhage score; MS Z total
microvasculopathy score; V Z vasodilatation score. A large
font size number denotes a correlation with p < 0.05.
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patients with RP, which indicated changes in the integrity
of the adherent junctions of endothelial cells. These find-
ings suggest that ischemiaereperfusion injury plays an
important role in the pathophysiology of RP, and that al-
terations of endothelial integrity are probably required to
cause microvascular hemorrhage.
EMPs have an endothelium-dependent vasodilatation
effect, as the EMPs isolated from patients with end-stage
renal failure have been shown to impair endothelium-
dependent vasodilatation in vitro.31 In clinical studies,
EMP level was reported to have an inverse correlation with
artery relaxation.32,33 These findings suggest that the
endothelial-dependent vasoregulation may play a critical
role in the pathogenesis of RP, although the exact effects of
EMPs require future investigations.
Nailfold capillaroscopy is a noninvasive method to access
microvasculopathy in patients with AID and RP. Widefield
nailfold capillaroscopy using a stereomicroscope as in thePlease cite this article in press as: Wu Y-JJ, et al., The role of endothe
phenomenon, Journal of Microbiology, Immunology and Infection (201present study has been shown to be significantly correlated
with videocapillaroscopy in patients with RP.34 Morphologic
alterations of the microcirculation have been associated
with systemic vascular damage and disease activity,35 and
microvascular abnormalities are relevant to tissue hypoxia.
Loss of capillaries (the avascular area) represents critical
tissue hypoxia and is associated with a poor prognosis. We
demonstrated that the annexin Vþ MP is significantly
correlated with the severity of microangiopathy and avas-
cular area, but EMP lacks similar correlation. In this study,
we measured total Annexin Vþ MPs shed from various cells,
including platelets, white blood cells, and endothelium.
The aforementioned results suggest the potential role of
phosphotidylserine-bearing MPs in the pathogenesis of
microvasculopathy in secondary RP, but not only shed from
endothelium. In particular, platelet activation also con-
tributes to the pathogenesis of RP,5 and the activated
platelets release MPs with procoagulant activities that rely
on the exposure of PS and involve vascular injury.10 How-
ever, the precise mechanisms require further investigation.
In conclusion, circulating EMPs and phosphatidylserine-
bearing MPs are elevated in AID patients with RP, and
annexin Vþ MPs are significantly correlated with the
severity of microangiopathy. EMPs may serve as a potential
surrogate biomarker to reflect the endothelial activation
and damage in secondary RP.Conflicts of interest
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